TREPROSTINIL and COUGH

Overview

COUGH is the #5 most commonly reported adverse reaction for TREPROSTINIL, manufactured by United Therapeutics Corporation. There are 10,541 FDA adverse event reports linking TREPROSTINIL to COUGH. This represents approximately 3.4% of all 313,927 adverse event reports for this drug.

TREPROSTINIL has an overall safety score of 85 out of 100. Patients taking TREPROSTINIL who experience cough should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.

Reporting Frequency

COUGH is moderately reported among TREPROSTINIL users, representing a notable but not dominant share of adverse events.

Other Side Effects of TREPROSTINIL

In addition to cough, the following adverse reactions have been reported for TREPROSTINIL:

• DYSPNOEA — 20,295 reports
• HEADACHE — 16,274 reports
• DIARRHOEA — 13,136 reports
• NAUSEA — 11,858 reports
• DIZZINESS — 8,870 reports
• FATIGUE — 8,812 reports
• DEATH — 8,777 reports
• VOMITING — 6,084 reports
• INFUSION SITE PAIN — 5,510 reports
• HYPOTENSION — 5,419 reports

Other Drugs Associated with COUGH

The following drugs have also been linked to cough in FDA adverse event reports:

Does TREPROSTINIL cause COUGH?

COUGH has been reported as an adverse event in 10,541 FDA reports for TREPROSTINIL. This does not prove causation, but indicates an association observed in post-market surveillance data.

How common is COUGH with TREPROSTINIL?

COUGH accounts for approximately 3.4% of all adverse event reports for TREPROSTINIL, making it a notable side effect.

What should I do if I experience COUGH while taking TREPROSTINIL?

If you experience cough while taking TREPROSTINIL, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.

Related Pages